使用孟德尔随机化分析分析,对降低LDL-c的药物和门性高血压之间的遗传关联分析
Qing-Ao Xiao1,2, Xiao-Long Li1,2, Lei Qin1,2
1Department of Interventional Radiology, the First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, Hubei Province, China.
Scientific reports
|July 2, 2025
概括
这项研究表明,NPC1L1抑制可以通过影响组织因素来治疗门门高血压 (PH),而不仅仅是降低胆固醇. 需要进一步的研究来探索NPC1L1抑制剂的潜在副作用.
科学领域:
- 药物基因组学 药物基因组学
- 心血管研究研究心血管研究
- 肝病学 肝病学是一种肝病学.
背景情况:
- 临床指导方针提倡使用他类药物治疗门高血压 (PH).
- 非他类降脂剂在PH中的作用缺乏人口级数据.
- 门德尔随机化 (MR) 提供了一种新的方法来调查遗传关联.
研究的目的:
- 通过MR分析,研究常用的低密度脂蛋白胆固醇 (LDL-c) 降低药物对门高血压 (PH) 的影响.
- 探索PH治疗中NPC1L1抑制剂的潜在机制和潜在副作用.
主要方法:
- 使用孟德尔随机化 (MR) 分析与GWAS的仪器变量对八种降脂药物相关基因.
- 作为阳性对照,进行了冠状动脉疾病 (CAD) 的MR分析.
- 使用eQTL数据进行了基于摘要的门德尔随机化 (SMR) 和调解分析.
主要成果:
- 较低的CETP和NPC1L1表达与门口压力降低有关.
- SMR分析证实了NPC1L1与PH (OR:0.648,P=7.502e-3) 的相关性.
- NPC1L1对PH的治疗效果部分由组织因子 (18.52%效果) 介导,独立于LDL-c降低. NPC1L1抑制剂可能与23种疾病有关.
结论:
- NPC1L1,不仅仅是LDL-c的降低,通过组织因子调节显示出对PH的潜在治疗效果.
- 遗传相关性分析提供了关于NPC1L1在PH中的机制的见解.
- 对NPC1L1抑制剂的潜在副作用需要进一步研究.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
884
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
884
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Factors Influencing Drug Absorption: Disease States and Pharmacology
830
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
830
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
86
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
86


